

Oliver Machholdt

Partner (Copenhagen)



Oliver Machholdt specialises in transactions, contracts and regulatory matters in the Life Science industry.

He advises Danish and foreign clients on transactions, contracts and regulatory matters in relation to biotech, pharmaceuticals, medical devices, medicinal cannabis, and food products. He receives particular acclaim for his knowledge of the Life Science industry.

He is an experienced adviser in complex international transactions involving pharmaceuticals and medical devices and the drafting and negotiation of commercial contracts such as service agreements, licence agreements, manufacturing agreements and supply agreements.

Oliver also assists clients in the Life Science industry on regulatory issues, including relating to authorisations, clinical trials, cooperation between the industry and healthcare professionals, and advertising of pharmaceuticals and medical devices.

Dir. +45 38 77 46 06
Mob. +45 61 20 11 74
omh@kromannreumert.com

[LinkedIn](#)

Practice areas

[Corporate and Foundation](#)

[Law](#)

[Life Science](#)

[M&A](#)

Industries

[Healthcare](#)

Oliver has extensive experience in drafting and negotiating contracts with Danish and foreign universities and other public research institutions and CROs, including non-disclosure agreements, material transfer agreements, clinical trial agreements, and R&D agreements.

High-profile cases

Oliver has been involved in a large number of high-profile cases in the Life Science industry, including:

- Little Green Pharma's acquisition of a large Danish medicinal cannabis manufacturer
- KKR's investment in Nordic Bioscience
- Investcorp's acquisition of the Sanos Group
- Orifarm's purchase of a portfolio of 110 medicinal products and dietary supplements and two production facilities from Takeda
- The sale of Glycom to DSM
- LEO Pharma's sale of pharmaceutical product portfolios to Karo Pharma
- Axcel's acquisition of European Sperm Bank
- Aurora Cannabis' setting up of a Danish joint venture for the production of cannabis
- Adviser to the shareholders in Widex in connection with the merger between Widex and Sivantos
- Mölnlycke Healthcare's acquisition of M&J Airlaid Products
- Natus Medical's acquisition of GN's global Otometrics division
- LEO Pharma's conclusion of a global licence agreement for Tralokinumab and a European licence agreement for Brodalumab, and its strategic cooperation with AstraZeneca
- LEO Pharma's acquisition of Astellas' global dermatology portfolio.

Ratings

Oliver is rated in [IFLR1000](#) (Notable practitioner) and in [Who's Who Legal Life Sciences](#) (Leading Lawyer) guide for Denmark.

Background

Career

- Partner, Kromann Reumert, 2020-
- Kromann Reumert, 2006-

Education

- Admitted to practise law 2011
- Master of Laws (*cand. jur.*), University of Copenhagen, 2008

Languages

- Danish
- English

Activities

- Member of the board of the Danish Life Science Law Association
- Member of the association Life Science Law DK
- Lecturer in advanced property law (debt enforcement and insolvency law) at the University of Copenhagen, 2011-2012
- Studies at University of San Diego, California, 2007